Potential molecular mechanism underlying cardiac fibrosis in diabetes mellitus: a narrative review

Boyko EJ, Karuranga S, Magliano DJ, Saedi P, Sun H (2021) International diabetes federation (IDF) diabetes atlas 10th edition [internet]. International Diabetes Federation. www.diabetesatlas.org

World Health Organization (2021) Diabetes [Internet]. https://www.who.int/news-room/fact-sheets/detail/diabetes

Alam S, Hasan MK, Neaz S, Hussain N, Hossain MF, Rahman T (2021) Diabetes mellitus: insights from epidemiology, biochemistry, risk factors, diagnosis, complications and comprehensive management. Diabetology. 2:36–50

Turkbey EB, Backlund JYC, Genuth S, Jain A, Miao C, Cleary PA et al (2011) Myocardial structure, function, and scar in patients with type 1 diabetes mellitus. Circulation 124:1737–1746

Kashiwagi A, Araki S, Maegawa H (2021) Sodium–glucose cotransporter 2 inhibitors represent a paradigm shift in the prevention of heart failure in type 2 diabetes patients. J Diabetes Investig [Internet] 12:6–20. https://doi.org/10.1111/jdi.13329

Pancholia AK (2018) Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus. Indian Heart J 70:915–921

Emdin CA, Anderson SG, Callender T, Conrad N, Salimi-Khorshidi G, Mohseni H et al (2015) Usual blood pressure, peripheral arterial disease, and vascular risk: cohort study of 4.2 million adults. BMJ [Internet]. https://doi.org/10.1136/bmj.h4865

Bujak M, Frangogiannis NG (2007) The role of TGF-β signaling in myocardial infarction and cardiac remodeling. Cardiovasc Res 74:184–195

Yuan J, Chen H, Ge D, Xu Y, Xu H, Yang Y et al (2017) Mir-21 promotes cardiac fibrosis after myocardial infarction via targeting Smad7. Cell Physiol Biochem 42:2207–2219

Fauchier L, Boriani G, de Groot JR, Kreutz R, Rossing P, Camm AJ (2021) Medical therapies for prevention of cardiovascular and renal events in patients with atrial fibrillation and diabetes mellitus. EP Europ 23:1–19

Lee HC, Shiou YL, Jhuo SJ, Chang CY, Liu PL, Jhuang WJ et al (2019) The sodium-glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats. Cardiovasc Diabetol BioMed Central 18:1–13

Biernacka A, Cavalera M, Wang J, Russo I, Shinde A, Kong P et al (2015) Smad3 signaling promotes fibrosis while preserving cardiac and aortic geometry in obese diabetic mice. Circ Heart Fail 8:788–798

González A, Schelbert EB, Díez J, Butler J (2018) Myocardial interstitial fibrosis in heart failure: biological and translational perspectives. J Am Coll Cardiol 71:1696–1706

Zhang F, Dang Y, Li Y, Hao Q, Li R, Qi X (2016) Cardiac contractility modulation attenuate myocardial fibrosis by inhibiting TGF-β1/Smad3 signaling pathway in a rabbit model of chronic heart failure. Cell Physiol Biochem 39:294–302

Oral EA (2016) Closing the knowledge gap on cardiovascular disease in type 2 diabetes: the EMPA-REG OUTCOME trial and beyond. Drugs Context 5:1–10

Verma S, Klug E, Mareev VY, Kobalava ZD, Connelly KA, Arici M et al (2020) Sodium-glucose cotransporter 2 inhibitors at the intersection of cardiovascular, renal and metabolic care: an integrated and multidisciplinary approach to patient-centered care. Curr Opin Cardiol 35:589–601

Wong TC, Piehler KM, Kang IA, Kadakkal A, Kellman P, Schwartzman DS et al (2014) Myocardial extracellular volume fraction quantified by cardiovascular magnetic resonance is increased in diabetes and associated with mortality and incident heart failure admission. Eur Heart J 35:657–664

Almdal T, Scharling H, Jensen JS, Vestergaard H (2004) The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death: a population-based study of 13,000 men and women with 20 years of follow-up. Arch Intern Med [Internet] 164:1422–1426

Bertoia ML, Allison MA, Manson JE, Freiberg MS, Kuller LH, Solomon AJ et al (2012) Risk factors for sudden cardiac death in post-menopausal women. J Am Coll Cardiol 60:2674–2682

Münch AJ, Avanesov M, Bannas P, Säring D, Krämer E, Mearini G et al (2016) Serum matrix metalloproteinases as quantitative biomarkers for myocardial fibrosis and sudden cardiac death risk stratification in patients with hypertrophic cardiomyopathy. J Card Fail 22:845–850

Grisanti LA (2018) Diabetes and arrhythmias: pathophysiology, mechanisms and therapeutic outcomes. Front Physiol 9:1–15

Ceriello A, Catrinoiu D, Chandramouli C, Cosentino F, Dombrowsky AC, Itzhak B et al (2021) Heart failure in type 2 diabetes: current perspectives on screening, diagnosis and management. Cardiovasc Diabetol BioMed Central 20:1–19

Dunlay SM, Givertz MM, Aguilar D, Allen LA, Chan M, Desai AS et al (2019) Type 2 diabetes mellitus and heart failure a scientific statement from the American Heart Association and the Heart Failure Society of America. Circulation 140:e294–e324

Murtha LA, Schuliga MJ, Mabotuwana NS, Hardy SA, Waters DW, Burgess JK et al (2017) The processes and mechanisms of cardiac and pulmonary fibrosis. Front Physiol 8:1–15

Kalosakas G, Ngai KL, Flach S (2005) Breather-induced anomalous charge diffusion. Phys Rev E [Internet] 71:061901. https://doi.org/10.1103/PhysRevE.71.061901

Westermann D, Rutschow S, Jäger S, Linderer A, Anker S, Riad A et al (2007) Contributions of inflammation and cardiac matrix metalloproteinase activity to cardiac failure in diabetic cardiomyopathy: the role of angiotensin type 1 receptor antagonism. Diabetes 56:641–646

van Linthout S, Seeland U, Riad A, Eckhardt O, Hohl M, Dhayat N et al (2008) Reduced MMP-2 activity contributes to cardiac fibrosis in experimental diabetic cardiomyopathy. Basic Res Cardiol 103:319–327

Shimizu M, Umeda K, Sugihara N, Yoshio H, Ino H, Takeda R et al (1993) Collagen remodelling in myocardia of patients with diabetes. J Clin Pathol 46:32–36

Gressner AM, Weiskirchen R (2006) Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-β β as major players and therapeutic targets. J Cell Mol Med 10:76–99

Engebretsen KVT, Skårdal K, Bjørnstad S, Marstein HS, Skrbic B, Sjaastad I et al (2014) Attenuated development of cardiac fibrosis in left ventricular pressure overload by SM16, an orally active inhibitor of ALK5. Curr Ther Res Clin Exp 76:148–157

Parichatikanond W, Luangmonkong T, Mangmool S, Kurose H (2020) Therapeutic targets for the treatment of cardiac fibrosis and cancer: focusing on tgf-β Signaling. Front Cardiovasc Med 7:1–19

Abed HS, Samuel CS, Lau DH, Kelly DJ, Royce SG, Alasady M et al (2013) Obesity results in progressive atrial structural and electrical remodeling: implications for atrial fibrillation. Heart Rhythm 10:90–100

Gao Y, Kang L, Li C, Wang X, Sun C, Li Q et al (2016) Resveratrol ameliorates diabetes-induced cardiac dysfunction through AT1R-ERK/p38 MAPK signaling pathway. Cardiovasc Toxicol 16:130–137

Li N, Zhou H, Tang Q (2018) miR-133: a suppressor of cardiac remodeling? Front Pharmacol 9:903

Dietrich C, Singh M, Kumar N, Singh SR (2018) The emerging roles of microRNAs in stem cell aging. In: Mettinger KL, Rameshwar P, Kumar V (eds) Exosomes, stem cells and MicroRNA: aging, cancer and age related disorders. Springer, Cham, pp 11–26

Xiao J, Tang X, Li Y, Fang Z, Ma D, He Y et al (2011) Identification of microRNA precursors based on random forest with network-level representation method of stem-loop structure. BMC Bioinform 12:1–8

Calin GA, Croce CM (2006) MicroRNA signatures in human cancers. Nat Rev Cancer [Internet] 6:857–866

Chen C, Ponnusamy M, Liu C, Gao J, Wang K, Li P (2017) MicroRNA as a therapeutic target in cardiac remodeling. Biomed Res Int [Internet] 2017:1–25

Disertori M, Masè M, Ravelli F (2017) Myocardial fibrosis predicts ventricular tachyarrhythmias. Trends Cardiovasc Med 27:363–372

Jellis C, Martin J, Narula J, Marwick TH (2010) Assessment of nonischemic myocardial fibrosis. J Am Coll Cardiol 56:89–97

Hinderer S, Schenke-Layland K (2019) Cardiac fibrosis: a short review of causes and therapeutic strategies. Adv Drug Deliv Rev [Internet] 146:77–82

Kurose H (2021) Cardiac fibrosis and fibroblasts. Cells 10:1716

Karamitsos TD, Arvanitaki A, Karvounis H, Neubauer S, Ferreira VM (2020) Myocardial tissue characterization and fibrosis by imaging. JACC Cardiovasc Imaging 13:1221–1234

Bing R, Dweck MR (2019) Myocardial fibrosis: why image, how to image and clinical implications. Heart 105:1832–1840

De Jong S, Van Veen TAB, Van Rijen HVM, De Bakker JMT (2011) Fibrosis and cardiac arrhythmias. J Cardiovasc Pharmacol 57:630–638

Umbarkar P, Ejantkar S, Tousif S, Lal H (2021) Mechanisms of fibroblast activation and myocardial fibrosis: lessons learned from FB-specific conditional mouse models. Cells 10:2412

Fu X, Khalil H, Kanisicak O, Boyer JG, Vagnozzi RJ, Maliken BD et al (2018) Specialized fibroblast differentiated states underlie scar formation in the infarcted mouse heart. J Clin Investig 128:2127–2143

Ma Y, Iyer RP, Jung M, Czubryt MP, Lindsey ML (2017) Cardiac fibroblast activation post-myocardial infarction: current knowledge gaps. Physiol Behav 38:448–458

Liu T, Song D, Dong J, Zhu P, Liu J, Liu W et al (2017) Current understanding of the pathophysiology of myocardial fibrosis and its quantitative assessment in heart failure. Front Physiol 8:1–13

Horn MA, Trafford AW (2016) Aging and the cardiac collagen matrix: Novel mediators of fibrotic remodelling. J Mol Cell Cardiol 93:175–185

Kong P, Christia P, Frangogiannis NG (2014) The pathogenesis of cardiac fibrosis. Cell Mol Life Sci 71:549–574

Díez J, González A, Kovacic JC (2020) Myocardial interstitial fibrosis in nonischemic heart disease, part 3/4: JACC focus seminar. J Am Coll Cardiol 75:2204–2218

Li L, Zhao Q, Kong W (2018) Extracellular matrix remodeling and cardiac fibrosis. Matrix Biol 68–69:490–506

Van Heerebeek L, Hamdani N, Handoko ML, Falcao-Pires I, Musters RJ, Kupreishvili K et al (2008) Diastolic stiffness of the failing diabetic heart: Importance of fibrosis, advanced glycation end products, and myocyte resting tension. Circulation 117:43–51

Yap J, Tay WT, Teng THK, Anand I, Richards AM, Ling LH et al (2019) Association of diabetes mellitus on cardiac remodeling, quality of life, and clinical outcomes in heart failure with reduced and preserved ejection fraction. J Am Heart Assoc 8:e013114

Paulus WJ, Dal Canto E (2018) Distinct myocardial targets for diabetes therapy in heart failure with preserved or reduced ejection fraction. JACC Heart Fail 6:1–7

Basta G, Schmidt AM, De Caterina R (2004) Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc Res 63:582–592

Russo I, Frangogiannis NG (2016) Molecular mechanisms and therapeutic opportunities. J Mol Cell Cardiol 90:84–93

Shinde AV, Frangogiannis NG (2014) Fibroblasts in myocardial infarction: a role in inflammation and repair. J Mol Cell Cardiol 70:74–82

van Putten S, Shafieyan Y, Hinz B (2016) Mechanical control of cardiac myofibroblasts. J Mol Cell Cardiol 93:133–142

Dewald O, Zymek P, Winkelmann K, Koerting A, Ren G, Abou-Khamis T et al (2005) CCL2/monocyte chemoattractant protein-1 regulates inflammatory responses critical to healing myocardial infarcts. Circ Res 96:881–889

Frieler RA, Mortensen RM (2015) Immune cell and other noncardiomyocyte regulation of cardiac hypertrophy and remodeling. Circulation 131:1019–1030

Humphreys BD (2012) Targeting pericyte differentiation as a strategy to modulate kidney fibrosis in diabetic nephropathy. Semin Nephrol 32:463–470

Nishikori Y, Shiota N, Okunishi H (2014) The role of mast cells in cutaneous wound healing in streptozotocin-induced diabetic mice. Arch Dermatol Res 306:823–835

Zhang W, Chancey AL, Tzeng H-P, Zhou Z, Lavine KJ, Gao F et al (2011) The development of myocardial fibrosis in transgenic mice with targeted overexpression of tumor necrosis factor requires mast cell-fibroblast interactions. Circulation 124:2106–2116

Rose BA, Force T, Wang Y (2010) Mitogen-activated protein kinase signaling in the heart: angels versus demons in a heart-breaking tale. Physiol Rev 90:1507–1546

Tachibana H, Perrino C, Takaoka H, Davis RJ, Naga Prasad SV, Rockman HA (2006) JNK1 is required to preserve cardiac function in the early response to pressure overload. Biochem Biophys Res Commun 343:1060–1066

Kyoi S, Otani H, Matsuhisa S, Akita Y, Tatsumi K, Enoki C et al (2006) Opposing effect of p38 MAP kinase and JNK inhibitors on the development of heart failure in the cardiomyopathic hamster. Cardiovasc Res 69:888–898

Krishnamurthy P, Subramanian V, Singh M, Singh K (2007) Β1 integrins modulate B-adrenergic receptor-stimulated cardiac myocyte apoptosis and myocardial remodeling. Hypertension 49:865–872

Liao P, Georgakopoulos D, Kovacs A, Zheng M, Lerner D, Pu H et al (2001) The in vivo role of p38 MAP kinases in cardiac remodeling and restrictive cardiomyopathy. Proc Natl Acad Sci U S A 98:12283–12288

Rincón M, Davis RJ (2009) Regulation of the immune response by stress-activated protein kinases. Immunol Rev 228:212–224

Kyriakis JM, Avruch J (2001) Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev 81:807–869

Hanna A, Humeres C, Frangogiannis NG (2021) The role of Smad signaling cascades in cardiac fibrosis. Cell Signal 77:109826

Bujak M, Ren G, Kweon HJ, Dobaczewski M, Reddy A, Taffet G et al (2007) Essential role of Smad3 in infarct healing and in the pathogenesis of cardiac remodeling. Circulation 116:2127–2138

Russo I, Cavalera M, Huang S, Su Y, Hanna A, Chen B et al (2019) Protective effects of activated myofibroblasts in the pressure-overloaded myocardium are mediated through smad-dependent activation of a matrix-preserving program. Circ Res 124:1214–1227

Raftery LA, Twombly V, Wharton K, Gelbart WM (1995) Genetic screens to identify elements of the decapentaplegic signaling pathway in Drosophila. Genetics 139:241–254

Kretzschmar M, Massagué J (1998) SMADs: mediators and regulators of TGF-β signaling. Curr Opin Genet Dev 8:103–111

Hata A, Chen Y-G (2016) TGF-β signaling from receptors to smads. Cold Spring Harb Perspect Biol 8:a022061

Chen C, Ponnusamy M, Liu C, Gao J, Wang K, Li P (2017) MicroRNA as a therapeutic target in cardiac remodeling. Biomed Res Int 2017:1278436

Li N, Zhou H (2020) Sglt2 inhibitors: a novel player in the treatment and prevention of diabetic cardiomyopathy. Drug Des Devel Ther 14:4775–4788

Wakisaka M, Kamouchi M, Kitazono T (2019) Lessons from the trials for the desirable effects of sodium glucose co-transporter 2 inhibitors on diabetic cardiovascular events and renal dysfunction. Int J Mol Sci 20:1–15

Borghetti G, Von LD, Eaton DM, Sourij H, Houser SR, Wallner M (2018) Diabetic cardiomyopathy: current and future therapies. Beyond Glycemic Control 9:1–15

Dai B, Wang F, Nie X, Du H, Zhao Y, Yin Z et al (2020) The cell type-specific functions of miR-21 in cardiovascular diseases. Front Genet [Internet] 11:1–16. https://doi.org/10.3389/fgene.2020.563166/full

Spinale FG, Janicki JS, Zile MR, Spinale FG, Janicki JS, Zile MR (2013) Membrane-associated matrix proteolysis and heart failure. Circ Res 112:195–208

del Monte-Nieto G, Fischer JW, Gorski DJ, Harvey RP, Kovacic JC (2020) Basic biology of extracellular matrix in the cardiovascular system, part 1/4: JACC focus seminar. J Am Coll Cardiol 75:2169–2188

Zile MR, DeSantis SM, Baicu CF, Stroud RE, Thompson SB, McClure CD et al (2011) Plasma biomarkers that reflect determinants of matrix composition identify the presence of left ventricular hypertrophy and diastolic heart failure. Circ Heart Fail [Internet] 4:246–256. https://doi.org/10.1161/CIRCHEARTFAILURE.110.958199

Marchesi C, Dentali F, Nicolini E, Maresca AM, Tayebjee MH, Franz M et al (2012) Plasma levels of matrix metalloproteinases and their inhibitors in hypertension: a systematic review and meta-analysis. J Hypertens 30:3–16

Matsusaka H, Ide T, Matsushima S, Ikeuchi M, Kubota T, Sunagawa K et al (2006) Targeted deletion of matrix metalloproteinase 2 ameliorates myocardial remodeling in mice with chronic pressure overload. Hypertension 47:711–717

Wu L, Derynck R (2009) Essential role of TGF-β signaling in glucose-induced cell hypertrophy. Dev Cell 17:35–48

Bonnans C, Chou J, Werb Z (2014) Remodelling the extracellular matrix in development and disease. Nat Rev Mol Cell Biol [Internet] 15:786–801

Martos R, Baugh J, Ledwidge M, O’Loughlin C, Conlon C, Patle A et al (2007) Diastolic heart failure: evidence of increased myocardial collagen turnover linked to diastolic dysfunction. Circulation 115:888–895

López B, González A, Querejeta R, Larman M, Díez J (2006) Alterations in the pattern of collagen deposition may contribute to the deterioration of systolic function in hypertensive patients with heart failure. J Am Coll Cardiol 48:89–96

Zelniker TA, Braunwald E (2020) Mechanisms of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors: JACC state-of-the-art review. J Am Coll Cardiol 75:422–434

Habibi J, Aroor AR, Sowers JR, Jia G, Hayden MR, Garro M et al (2017) Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes. Cardiovasc Diabetol BioMed Central 16:1–15

Kraakman MJ, Lee MKS, Al-Sharea A, Dragoljevic D, Barrett TJ, Montenont E et al (2017) Neutrophil-derived S100 calcium-binding proteins A8/A9 promote reticulated thrombocytosis and atherogenesis in diabetes. J Clin Investig 127:2133–2147

Kuwahara F, Kai H, Tokuda K, Takeya M, Takeshita A, Egashira K et al (2004) Hypertensive myocardial fibrosis and diastolic dysfunction: another model of inflammation? Hypertension 43:739–745

Arow M, Waldman M, Yadin D, Nudelman V, Shainberg A, Abraham NG et al (2020) Sodium-glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy. Cardiovasc Diabetol BioMed Central 19:1–12

Dadson K, Kovacevic V, Sweeney G (2015) Mechanisms of cardiac fibrosis and heart failure. Cardiac fibrosis and heart failure: cause or effect? Springer, Cham, pp 279–297

Lijnen P, Papparella I, Petrov V, Semplicini A, Fagard R (2006) Angiotensin II-stimulated collagen production in cardiac fibroblasts is mediated by reactive oxygen species. J Hypertens 24:757–766

Kim M, Zhang X (2019) The profiling and role of miRNAs in diabetes mellitus. J Diabetes Clin Res 1:5–23

Zhao Y, Du D, Chen S, Chen Z, Zhao J (2022) New insights into the functions of MicroRNAs in cardiac fibrosis: from mechanisms to therapeutic strategies. Genes (Basel) [Internet] 13:1390–1406

Guo R, Nair S (2017) Role of microRNA in diabetic cardiomyopathy: from mechanism to intervention. Biochim Biophys Acta Mol Basis Dis 1863:2070–2077

Kong L, Zhu J, Han W, Jiang X, Xu M, Zhao Y et al (2011) Significance of serum microRNAs in pre-diabetes and newly diagnosed type 2 diabetes: a clinical study. Acta Diabetol 48:61–69

Karolina DS, Armugam A, Tavintharan S, Wong MTK, Lim SC, Sum CF et al (2011) MicroRNA 144 impairs insulin signaling by inhibiting the expression of insulin receptor substrate 1 in type 2 diabetes mellitus. PLoS ONE [Internet] 6:e22839. https://doi.org/10.1371/journal.pone.0022839

Sweeney M, Corden B, Cook SA (2020) Targeting cardiac fibrosis in heart failure with preserved ejection fraction: mirage or miracle? EMBO Mol Med 12:1–26

Brilla CG, Funck RC, Rupp H (2000) Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation 102:1388–1393

Berezin A (2002) Angiotensin-II receptor antagonist losartan dose-dependently improves the left ventricular remodelling in patients with congestive heart failure. J Clin Basic Cardiol [Internet] 5:83–86

McDiarmid AK, Swoboda PP, Erhayiem B, Bounford KA, Bijsterveld P, Tyndall K et al (2020) Myocardial effects of aldosterone antagonism in heart failure with preserved ejection fraction. J Am Heart Assoc 9:1–10

McMurray JJV, Packer M, Desai AS, Gong J (2017) Angiotensin–neprilysin inhibition versus enalapril in heart failure. Rev Argent Med 5:132–133

Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP et al (2019) Angiotensin–neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med 381:1609–1620

McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M et al (2021) 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 42:3599–3726

Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM et al (2022) 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. Circulation 145:e895-1032

Rog-Zielinska EA, Norris RA, Kohl P, Markwald R (2016) The living scar—cardiac fibroblasts and the injured heart. Trends Mol Med 22:99–114